FDA Approval
FDA Approves Bausch Health's DUOBRII™ (Halobetasol Propionate And Tazarotene) Lotion 0.01%/0.045% For Plaque Psoriasis In Adults
Bausch Health Companies Inc.
PR-M04-19-NI-082Apr 26, 2019
Acquistion
Bausch Health Completes Acquisition Of Certain Assets Of Synergy Pharmaceuticals Inc.
Nice Insight
PR-M03-19-NI-023Mar 08, 2019
Dermatology
Bausch Health's Ortho Dermatologics Business To Present New Scientific Data During The Fall Clinical Dermatology Conference
Bausch Health Companies Inc.
PR-M10-18-NI-069Oct 19, 2018
FDA Approval
Bausch Health's BRYHALI™(halobetasol propionate) Lotion, 0.01%, Receives Tentative FDA Approval For Plaque Psoriasis In Adults
Bausch Health Companies Inc.
PR-M10-18-NI-033Oct 10, 2018
Announcement
Bausch Health Companies Inc. Completes Name Change
Bausch Health Companies Inc.
PR-M07-18-NI-048Jul 16, 2018